| Title | The pharmacological role of histone demethylase JMJD3 inhibitor GSK-J4 on glioma cells |
| Authors | Sui, Aixia Xu, Yongbing Li, Yitong Hu, Qilu Wang, Zeyang Zhang, Hongtao Yang, Junjie Guo, Xiaoqiang Zhao, Wenqing |
| Affiliation | Hebei Med Univ, Fac Grad Studies, Shijiazhuang 050081, Hebei, Peoples R China. Hebei Gen Hosp, Dept Oncol, Shijiazhuang 050051, Hebei, Peoples R China. Hebei Gen Hosp, Dept Neurosurg, Shijiazhuang 050051, Hebei, Peoples R China. Shenzhen Univ, Affliated Hosp 1, Shenzhen Peoples Hosp 2, Key Lab Med Reprogramming Technol,State Engn Lab, Shenzhen 518035, Guangdong, Peoples R China. Peking Univ, Shenzhen Hosp, Inst Urol Shenzhen, PKU HKUST Med Ctr,Dept Urol, Shenzhen 518036, Guangdong, Peoples R China. Hebei Med Univ, Fac Grad Studies, Shijiazhuang 050081, Hebei, Peoples R China. Zhao, WQ (reprint author), Hebei Gen Hosp, Dept Neurosurg, Shijiazhuang 050051, Hebei, Peoples R China. Guo, XQ (reprint author), Shenzhen Univ, Affliated Hosp 1, Shenzhen Peoples Hosp 2, Key Lab Med Reprogramming Technol,State Engn Lab, Shenzhen 518035, Guangdong, Peoples R China. Guo, XQ (reprint author), Peking Univ, Shenzhen Hosp, Inst Urol Shenzhen, PKU HKUST Med Ctr,Dept Urol, Shenzhen 518036, Guangdong, Peoples R China. |
| Keywords | glioma histone demethylase JMJD3 inhibitor GSK-J4 ACUTE LYMPHOBLASTIC-LEUKEMIA INTRINSIC PONTINE GLIOMAS CELLULAR SENESCENCE EPIGENETIC THERAPY CANCER UTX MUTATIONS KDM6B GSKJ4 |
| Issue Date | 2017 |
| Publisher | ONCOTARGET |
| Citation | ONCOTARGET.2017,8(40),68591-68598. |
| Abstract | Glioma is regarded as the most prevalent malignant carcinoma of the central nervous system, and lack of effective treatment. Thus, the development of new therapeutic strategies targeting glioma is of significant clinical importance. In the present study, histone H3K27 demethylase jumonji domain-containing protein 3 (JMJD3) was investigated as target for glioma treatment. The mRNA of JMJD3 was overexpressed in glioblastoma tissues compared to normal brain tissues (P<0.05). The content of JMJD3 was also higher in glioma cells than in human brain microvascular endothelial cell (hCMEC), and the corresponding level of H3K27me3 was decreased (P<0.05). The treatment with JMJD3 specific inhibitor GSK-J4 can increase the content of H3K27me3 in glioma cells, which means the activity of JMJD3 was inhibited. GSK-J4 can inhibit glioma cell proliferation in a concentration dependent and time-dependent manner (P<0.05). GSK-J4 also induced glioma cell apoptosis and inhibited cell migration (P<0.05). But there was no obvious effect of GSK-J4 on hCMEC cells. All together, these data suggest that GSK-J4 has important potential in the gliomas treatment. |
| URI | http://hdl.handle.net/20.500.11897/470846 |
| ISSN | 1949-2553 |
| Indexed | SCI(E) |
| Appears in Collections: | 深圳医院 |
